Viracta Therapeutics Announces Positive Topline Nana-val Results from Stage 1 of the NAVAL-1 Trial in Patients with Relapsed or Refractory Epstein-Barr Virus-Positive (EBV+) Peripheral T-Cell LymphomaGlobeNewsWire • Monday
Viracta Therapeutics to Present Topline Nana-val Results from Stage 1 of the NAVAL-1 Trial at the 2024 Annual Congress of The Hematology Society of TaiwanGlobeNewsWire • 04/01/24
Viracta Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business UpdateGlobeNewsWire • 03/07/24
Viracta Therapeutics Announces Completion of Second-Stage Enrollment into the Peripheral T-Cell Lymphoma Cohort of the NAVAL-1 TrialGlobeNewsWire • 02/29/24
Viracta Therapeutics to Present at the Oppenheimer 34th Annual Healthcare Life Sciences ConferenceGlobeNewsWire • 02/06/24
Viracta Therapeutics Announces Orphan Drug Designation Granted by the U.S. FDA to Nana-val for the Treatment of Nasopharyngeal CarcinomaGlobeNewsWire • 12/12/23
Viracta Therapeutics Announces Interim Data from Phase 1b/2 Clinical Trial of Nana-val in Patients with Epstein-Barr Virus-Positive Solid Tumors that Show Confirmed Tumor Responses at Higher Dose LevelsGlobeNewsWire • 12/04/23
Viracta Therapeutics Reports Third Quarter 2023 Financial Results and Provides Business UpdateGlobeNewsWire • 11/09/23
Viracta Therapeutics to Host R&D Day Highlighting Nana-val in Epstein-Barr Virus (EBV)-Associated CancersGlobeNewsWire • 10/04/23
Viracta Therapeutics Reports Second Quarter 2023 Financial Results and Provides Business UpdateGlobeNewsWire • 08/14/23
Viracta Therapeutics Announces Publication in Blood Advances Demonstrating Promising and Durable Signal of Nana-val Efficacy in Patients with Relapsed or Refractory (R/R) Epstein-Barr Virus-Positive (EBV+) LymphomaGlobeNewsWire • 08/08/23
Viracta Therapeutics' Pivotal NAVAL-1 Trial Achieves Efficacy Threshold for Expansion in Relapsed or Refractory EBV-positive Peripheral T-Cell Lymphoma (R/R EBV+ PTCL)GlobeNewsWire • 06/28/23
Viracta Therapeutics to Present at the RBC Capital Markets Global Healthcare ConferenceGlobeNewsWire • 05/11/23
Viracta Therapeutics Reports First Quarter 2023 Financial Results and Provides Clinical Program UpdatesGlobeNewsWire • 05/08/23
Viracta Therapeutics Reports Fourth Quarter and Full Year 2022 Financial Results and Provides a Corporate UpdateGlobeNewsWire • 03/13/23
Viracta Therapeutics to Present at the 33rd Annual Oppenheimer Healthcare ConferenceGlobeNewsWire • 03/08/23
Viracta Therapeutics to Present at the 2023 SVB Securities Global Biopharma ConferenceGlobeNewsWire • 02/07/23